Compare AGX & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AGX | ADPT |
|---|---|---|
| Founded | 1961 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Engineering & Construction | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.6B | 4.5B |
| IPO Year | 1995 | 2019 |
| Metric | AGX | ADPT |
|---|---|---|
| Price | $348.80 | $24.17 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 9 |
| Target Price | ★ $570.50 | $29.81 |
| AVG Volume (30 Days) | 353.9K | ★ 2.3M |
| Earning Date | 09-02-2026 | 11-04-2026 |
| Dividend Yield | ★ 0.54% | N/A |
| EPS Growth | 58.37 | ★ 63.89 |
| EPS | ★ 7.01 | N/A |
| Revenue | ★ $944,606,000.00 | $276,976,000.00 |
| Revenue This Year | $48.32 | $5.94 |
| Revenue Next Year | $20.43 | $22.42 |
| P/E Ratio | $52.32 | ★ N/A |
| Revenue Growth | 8.06 | ★ 54.77 |
| 52 Week Low | $257.62 | $12.00 |
| 52 Week High | $805.75 | $30.74 |
| Indicator | AGX | ADPT |
|---|---|---|
| Relative Strength Index (RSI) | 33.95 | 38.18 |
| Support Level | $333.39 | $23.73 |
| Resistance Level | $447.21 | $26.51 |
| Average True Range (ATR) | 17.71 | 1.45 |
| MACD | 1.18 | -0.48 |
| Stochastic Oscillator | 5.99 | 4.79 |
Argan Inc is a United States-based construction firm that conducts operations through its wholly-owned subsidiaries, GPS, APC, TRC, and SMC. Through GPS and APC it provides a full range of engineering, procurement, construction, commissioning, maintenance, project development and technical consulting services to the power generation market, including the renewable energy sector, for a wide range of customers, including independent power project owners, public utilities, power plant heavy equipment suppliers and other commercial firms with power requirements in the U.S., Ireland and the U.K. It operates in three segments: Power Services, Industrial Services, and Teledata, out of which Power Services derives the majority of revenue.
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.